• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRIMIPRAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • TRIMIPRAMINE chembl:CHEMBL644 Approved

    Alternate Names:

    IL-6001
    TRIMIPRAMINE
    SURMONTIL
    7162-RP
    TRIMEPROPRIMINE
    7162 RP
    SAPILENT
    TRIMEPRIMINE
    RP-7162
    5-(GAMMA-DIMETHYLAMINO-BETA-METHYLPROPYL)-10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPINE
    5-[3-(DIMETHYLAMINO)-2-METHYLPROPYL]-10,11-DIHYDRO-5H-DIBENZ[B,F]AZEPINE
    10,11-DIHYDRO-N,N,BETA-TRIMETHYL-5H-DIBENZ[B,F]AZEPINE-5-PROPANAMINE
    BETA-METHYLIMIPRAMINE
    SURMONTIL®
    chemidplus:739-71-9
    rxcui:10834
    drugbank:00726
    chembl:CHEMBL644
    pubchem.compound:5584

    Drug Info:

    Drug Categories psychoanaleptics
    Drug Categories non-selective monoamine reuptake inhibitors
    Drug Class antidepressive agents, tricyclic
    Year of Approval 1979
    FDA Approval 1979
    Drug Class small molecule
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Categories adrenergic alpha-1 receptor antagonists
    Drug Categories adrenergic alpha-antagonists
    Drug Categories adrenergic antagonists
    Drug Categories agents that produce hypertension
    Drug Categories agents that reduce seizure threshold
    Drug Categories combined inhibitors of serotonin/norepinephrine reuptake
    Drug Categories cytochrome p-450 cyp2b6 substrates
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 substrates
    Drug Categories heterocyclic compounds, fused-ring
    Drug Categories histamine antagonists
    Drug Categories histamine h1 antagonists
    Drug Categories neurotoxic agents
    Drug Categories p-glycoprotein substrates
    Drug Categories potential qtc-prolonging agents
    Drug Categories qtc prolonging agents
    Drug Categories serotonergic drugs shown to increase risk of serotonin syndrome
    Drug Categories serotonin 5-ht1 receptor antagonists
    Drug Categories serotonin 5-ht2 receptor antagonists
    Drug Categories serotonin agents
    Drug Categories serotonin receptor antagonists
    Drug Categories tertiary amine tricyclic antidepressants
    Drug Categories tricyclics and other norepinephrine-reuptake inhibitors
    (5 More Sources)

    Publications:

    Leathart JB et al., 1998, CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles., Pharmacogenetics
    de Vos A et al., 2011, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients., Pharmacogenomics J
    Dahl ML et al., 1992, Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population., Clin Pharmacol Ther
    Vandel P et al., 2004, Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients., Hum Psychopharmacol
    Roberts RL et al., 2004, No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline., Hum Psychopharmacol
    Forget P et al., 2008, Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study., J Pain Symptom Manage
    Kirchheiner J et al., 2003, Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics., J Clin Psychopharmacol
    Dahl ML et al., 1996, Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype., Psychopharmacology (Berl)
    Nielsen KK et al., 1994, Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms., Clin Pharmacol Ther
    Koski A et al., 2007, A fatal doxepin poisoning associated with a defective CYP2D6 genotype., Am J Forensic Med Pathol
    Tacke U et al., 1992, Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations., J Clin Psychopharmacol
    Schenk PW et al., 2008, Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients., Mol Psychiatry
    Furman KD et al., 2004, Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics., Pharmacogenetics
    Kirchheiner J et al., 2002, Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers., Pharmacogenetics
    Kirchheiner J et al., 2003, Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity., Pharmacogenetics
    Steimer W et al., 2004, Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers., Clin Chem
    Murphy GM Jr et al., 2001, CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression., Neuropsychopharmacology
    Koski A et al., 2006, CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies., Forensic Sci Int
    Eap CB et al., 2000, Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients., Ther Drug Monit
    Goetz MP et al., 2005, Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes., J Clin Oncol
    Johnson M et al., 2006, A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment., CNS Spectr
    Hicks JK et al., 2013, Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants., Clin Pharmacol Ther
    1999, Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG)., Clin Pharmacol Ther
    Dalén P et al., 1998, 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes., Clin Pharmacol Ther
    Stephan PL et al., 2006, Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity., Pharmacopsychiatry
    Berger et al., 1996, Trimipramine: a challenge to current concepts on antidepressives., Eur Arch Psychiatry Clin Neurosci
    Haenisch B et al., 2011, Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters., Psychopharmacology (Berl)
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Diamond et al., 2006, Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade., Eur Neuropsychopharmacol
    Eikmeier et al., 1990, High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial., Pharmacopsychiatry
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rudberg I et al., 2008, Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients., Eur J Clin Pharmacol
    Brøsen K et al., 1995, A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype., Pharmacogenetics
    Rudberg I et al., 2008, Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients., Clin Pharmacol Ther
    Desta Z et al., 2002, Clinical significance of the cytochrome P450 2C19 genetic polymorphism., Clin Pharmacokinet
    Wang JH et al., 2001, Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19., Clin Pharmacol Ther
    Sibbing D et al., 2010, Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement., Circulation
    de Morais SM et al., 1994, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans., J Biol Chem
    Grasmäder K et al., 2004, Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting., Eur J Clin Pharmacol
    Sim SC et al., 2006, A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants., Clin Pharmacol Ther
    Sibbing D et al., 2010, Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy., J Thromb Haemost
    Morinobu S et al., 1997, Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy., Psychiatry Clin Neurosci
    De Morais SM et al., 1994, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese., Mol Pharmacol
    Schenk PW et al., 2010, The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients., Pharmacogenomics J
    Koyama E et al., 1996, Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients., J Clin Psychopharmacol
    Swen JJ et al., 2011, Pharmacogenetics: from bench to byte--an update of guidelines., Clin Pharmacol Ther
  • TRIMIPRAMINE   SLC6A2

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    21484238 9537821 17139284 17016423


    Sources:
    TEND TdgClinicalTrial DrugBank GuideToPharmacology

  • TRIMIPRAMINE   SLC6A4

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Specific Action of the Ligand Inhibition

    PMIDs:
    9537821 16388933


    Sources:
    TEND TdgClinicalTrial DrugBank GuideToPharmacology

  • TRIMIPRAMINE   CYP2D6

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9918137 20531370 1346258 15252821 14716707 18359183 14520122 8867869 8181196 17721180 1527229 17667959 15115913 12360109 14646691 15205367 11682257 16024198 10774635 16361630 17008819 23486447 10460069 9585799 16871470


    Sources:
    FDA PharmGKB

  • TRIMIPRAMINE   CYP2C19

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18677622 20531370 8563772 14520122 17625515 12222994 11452243 20083681 8195181 15168101 16413245 20492469 9316174 7969038 10774635 19884907 8835703 23486447 21412232


    Sources:
    PharmGKB

  • TRIMIPRAMINE   SLC6A3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    9537821


    Sources:
    DrugBank GuideToPharmacology

  • TRIMIPRAMINE   HTR3A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   HTR1D

    Interaction Score: 0.08

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   HTR2C

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    11752352 8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   ADRA2B

    Interaction Score: 0.06

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   ADRA1B

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   DRD1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DTC DrugBank

  • TRIMIPRAMINE   ADRB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   ADRA2A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    negative modulator (inhibitory)

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   HTR1A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   CHRM1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    1979173


    Sources:
    DrugBank

  • TRIMIPRAMINE   ADRA1A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   HRH1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   HTR2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   DRD2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DrugBank

  • TRIMIPRAMINE   CBX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIMIPRAMINE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14520122


    Sources:
    PharmGKB

  • DrugBank: DB00726

    • Version: 5.1.7

    Alternate Names:
    739-71-9 CAS Number
    Apo-trimipramine Drug Brand
    Herphonal Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Categories adrenergic agents

    Publications:
    Berger et al., 1996, Trimipramine: a challenge to current concepts on antidepressives., Eur Arch Psychiatry Clin Neurosci
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Diamond et al., 2006, Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade., Eur Neuropsychopharmacol

  • TdgClinicalTrial: TRIMIPRAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Class small molecule
    FDA Approval 1979

    Publications:

  • TEND: TRIMIPRAMINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1979
    Drug Class antidepressive agents, tricyclic

    Publications:

  • PharmGKB: trimipramine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rudberg I et al., 2008, Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients., Eur J Clin Pharmacol
    de Vos A et al., 2011, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients., Pharmacogenomics J
    Brøsen K et al., 1995, A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype., Pharmacogenetics

  • DTC: TRIMIPRAMINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL644 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Trimipramine

    • Version: 2020.06.01

    Alternate Names:
    D00HZV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL644

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • GuideToPharmacology: 178103890

    • Version: 29-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Trimipramine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21